About the Company
9 meters biopharma, inc., a clinical-stage biotechnology company, focuses on patients with rare disorders and unmet needs. the company's pipeline includes drug candidates for short bowel syndrome (sbs) and celiac disease. it is developing nm-002, a long-acting injectable glp-1 agonist that is in a phase 2 clinical trial for sbs; and larazotide, a phase 3-stage therapeutic in development for celiac disease. the company also develops nm-003, a proprietary long-acting glp-2 agonist; and nm-004, a double-cleaved mesalamine with an immunomodulator for developing rare and/or orphan indications. 9 meters biopharma, inc. is based in raleigh, north carolina.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NMTR News
9 Meters Biopharma, Inc. (NMTRQ)
EMMA Emmaus Life Sciences, Inc.
After coeliac fail, 9 Meters plots phase 3 in short bowel syndrome
Two weeks after reporting disappointing results for its lead coeliac disease therapy, 9 Meters Biopharma will draw some comfort from a mid-stage trial of its candidate for short bowel syndrome ...
Biopharma M&A more than doubled in Q1 compared to the year prior: report
The number of biopharma M&A deals more than doubled in the first quarter of 2024 ... stock prices are up 29%. Vertex pays ...
First Wave BioPharma’s stock more than doubles after deal to sell its IBD treatment
Shares of First Wave BioPharma Inc. rocketed 123% in premarket trading ... while the iShares Biotechnology ETF has gained 9.7% and the S&P 500 has rallied 11.7%.
Aytu BioPharma, Inc. Common Stock (AYTU)
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of ARCA Biopharma, Inc. - ABIO
NEW YORK, April 9, 2024 /PRNewswire/ -- Monteverde & Associates ... Building in New York City and is investigating ARCA Biopharma, Inc. (Nasdaq: ABIO), relating to its proposed merger to Oruka ...
Benitec Biopharma Inc.: Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
April 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "Company"), a ... from the first ...
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical ... Separation of Michael Bristow, M.D., President, Chief Executive Officer and Director ...
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that ...
9 Meters Biopharma Inc. (NMTRQ)
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on ...
9 Meters Biopharma, Inc. (NMTRQ)
Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.
9 Meters Biopharma Inc (NMTRQ)
View advanced insights on the cash flow statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Loading the latest forecasts...